Duration of Eliquis (Apixaban) After Stroke
For stroke prevention in atrial fibrillation, Eliquis is typically continued indefinitely as long-term therapy, not stopped after a set period. 1
Long-Term Anticoagulation is Standard
Eliquis is approved for continuous use to reduce the risk of recurrent stroke and systemic embolism in patients with nonvalvular atrial fibrillation—there is no predetermined "stop date" after your initial stroke. 1
The FDA label explicitly warns: "If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant" because stopping increases your risk of another stroke. 1
Long-term safety and efficacy data extending beyond 3 years demonstrate that annual stroke rates remain low (approximately 1.0–1.1% per year) with continued apixaban therapy, supporting indefinite use. 2
When Timing Matters: Starting After Your Stroke
The evidence you've been given addresses when to start anticoagulation after a stroke, not when to stop:
- Minor stroke (NIHSS ≤5): Start within 48 hours. 3
- Moderate stroke (NIHSS 6–15): Start between days 3–7. 3
- Severe stroke (NIHSS >15): Delay until days 12–14. 3
- TIA: Start immediately. 3
Once initiated at the appropriate time based on stroke severity, the expectation is lifelong continuation unless contraindications develop. 4
Standard Dosing for Stroke Prevention
- Most patients: 5 mg twice daily. 1
- Dose-reduced to 2.5 mg twice daily if you meet at least 2 of these criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1
Why Stopping is Dangerous
In the ARISTOTLE trial that established Eliquis for stroke prevention, patients who stopped anticoagulation at study end had a threefold increase in stroke/embolism events (0.3% in the Eliquis arm vs. 0.1% in the warfarin arm during the 30-day transition period when some patients were inadequately anticoagulated). 1
Observational data show that discontinuing anticoagulation after acute stroke increases thrombotic events (11% vs. 3%, p=0.038) and worsens 90-day mortality (31% vs. 15%) compared to continuing therapy. 5
Common Pitfalls to Avoid
Do not confuse stroke prevention with VTE treatment: Eliquis for deep vein thrombosis/pulmonary embolism has a defined 6-month treatment course followed by optional extended prophylaxis at 2.5 mg twice daily. 1 Your stroke indication is different—it requires indefinite therapy.
Do not stop without discussing alternatives: If bleeding or other complications arise, your physician should transition you to another anticoagulant rather than leaving you unprotected. 1
Cerebral atherosclerosis may increase recurrent stroke risk: Patients with coexisting cerebral atherosclerotic lesions on MRI have higher rates of recurrent ischemic events (4.6% vs. 1.7%, p=0.036) even on apixaban, emphasizing the need for continued anticoagulation. 6
Bottom Line
You should plan to take Eliquis indefinitely unless your physician identifies a specific reason to stop (such as major bleeding, resolution of atrial fibrillation, or a contraindication). The goal is lifelong stroke prevention, not a fixed treatment duration. 1